Trial · NCT00696072
Results by group39
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 39
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population | Dasatinib Plus Letrozole | CBR (CR+PR+SD) | 40 | participants | |
| Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population | Letrozole | CBR (CR+PR+SD) | 40 | participants | |
| Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population | Dasatinib Plus Letrozole | CBR, DFI <= 2 Years | 20 | participants | |
| Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population | Letrozole | CBR, DFI <= 2 Years | 20 | participants | |
| Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population | Dasatinib Plus Letrozole | CBR, DFI > 2 Years | 20 | participants | |
| Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population | Letrozole | CBR, DFI > 2 Years | 20 | participants | |
| Number of Participants With Complete Response, Partial Response, Stable Disease, and Disease Progression | Dasatinib Plus Letrozole | CR | 1 | participants | |
| Number of Participants With Complete Response, Partial Response, Stable Disease, and Disease Progression | Letrozole | CR | 0 | participants | |
| Number of Participants With Complete Response, Partial Response, Stable Disease, and Disease Progression | Dasatinib Plus Letrozole | PR | 12 | participants | |
| Number of Participants With Complete Response, Partial Response, Stable Disease, and Disease Progression | Letrozole | PR | 15 | participants | |
| Number of Participants With Complete Response, Partial Response, Stable Disease, and Disease Progression | Dasatinib Plus Letrozole | SD | 32 | participants | |
| Number of Participants With Complete Response, Partial Response, Stable Disease, and Disease Progression | Letrozole | SD | 30 | participants | |
| Number of Participants With Complete Response, Partial Response, Stable Disease, and Disease Progression | Dasatinib Plus Letrozole | SD >=6 months | 27 | participants | |
| Number of Participants With Complete Response, Partial Response, Stable Disease, and Disease Progression | Letrozole | SD >=6 months | 25 | participants | |
| Number of Participants With Complete Response, Partial Response, Stable Disease, and Disease Progression | Dasatinib Plus Letrozole | PD | 7 | participants | |
| Number of Participants With Complete Response, Partial Response, Stable Disease, and Disease Progression | Letrozole | PD | 16 | participants | |
| Number of Participants With Complete Response, Partial Response, Stable Disease, and Disease Progression | Dasatinib Plus Letrozole | Not Evaluable | 4 | participants | |
| Number of Participants With Complete Response, Partial Response, Stable Disease, and Disease Progression | Letrozole | Not Evaluable | 0 | participants | |
| Median Progression Free Survival (PFS) - Intent to Treat (ITT) Population | Dasatinib Plus Letrozole | 20.1 | 95% Confidence Interval 10.7 to 28.4 | months | |
| Median Progression Free Survival (PFS) - Intent to Treat (ITT) Population | Letrozole | 9.9 | 95% Confidence Interval 7.4 to 19.8 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00696072/results